Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Phathom Pharmaceuticals Inc’s stock clocked out at $5.34, down -5.82% from its previous closing price of $5.67. In other words, the price has decreased by -$5.82 from its previous closing price. On the day, 1.22 million shares were traded.
Ratios:
To gain a deeper understanding of PHAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.68 and its Current Ratio is at 5.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 21 ’25 when Henderson Molly sold 6,583 shares for $6.59 per share. The transaction valued at 43,371 led to the insider holds 93,546 shares of the business.
Nabulsi Azmi sold 7,886 shares of PHAT for $51,957 on Jan 21 ’25. The Chief Operating Officer now owns 233,390 shares after completing the transaction at $6.59 per share. On Jan 21 ’25, another insider, Curran Terrie, who serves as the President and Chief Executive of the company, sold 19,109 shares for $6.59 each. As a result, the insider received 125,884 and left with 360,465 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 13.90.
Stock Price History:
Over the past 52 weeks, PHAT has reached a high of $19.71, while it has fallen to a 52-week low of $5.21. The 50-Day Moving Average of the stock is -22.29%, while the 200-Day Moving Average is calculated to be -53.55%.
Shares Statistics:
A total of 68.32M shares are outstanding, with a floating share count of 38.09M. Insiders hold about 44.29% of the company’s shares, while institutions hold 61.78% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is -$1.03, with high estimates of -$1.01 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$4.38 and -$5.45 for the fiscal current year, implying an average EPS of -$4.7. EPS for the following year is -$3.73, with 4.0 analysts recommending between -$3.46 and -$4.08.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $25.65M. It ranges from a high estimate of $30M to a low estimate of $21.15M. As of the current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $682kFor the next quarter, 7 analysts are estimating revenue of $28.54M. There is a high estimate of $30.1M for the next quarter, whereas the lowest estimate is $26M.
A total of 7 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $55.6M, while the lowest revenue estimate was $46.74M, resulting in an average revenue estimate of $51.25M. In the same quarter a year ago, actual revenue was $682kBased on 7 analysts’ estimates, the company’s revenue will be $166.01M in the next fiscal year. The high estimate is $197.82M and the low estimate is $137.29M.
